D. Warr

发表

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

M. Kris, A. Horwich, C. Buske, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Micrometastases in Sentinel Lymph Node Biopsies: The Medical Oncologist's Perspective: To Treat or Not to Treat?

N. Miller, D. Warr, 2003 .

Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer.

I. Tannock, P. Goss, Hanxian Hu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cognitive F unction, F atigue, a nd M enopausal S ymptoms i n Women R eceiving A djuvant C hemotherapy f or B reast C ancer

I. Tannock, P. Goss, Hanxian Hu, 2003 .

Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines

A. Molassiotis, F. Roila, I. Olver, 2005, Supportive Care in Cancer.

PREVENTION AND TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING AFTER EMETOGENIC CHEMOTHERAPY

D. Warr, 2005 .

Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study

G. Dranitsaris, D. Warr, P. Leung, 2001, Supportive Care in Cancer.

A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron

G. Dranitsaris, D. Warr, A. Puodziunas, 1995, Supportive Care in Cancer.

Standard treatment of chemotherapy-induced emesis

D. Warr, 2005, Supportive Care in Cancer.

Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications.

D. Payne, R. Feld, D. Killinger, 1993, Archives of internal medicine.

Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study

D. Cescon, P. Bedard, P. Goodwin, 2020, npj Breast Cancer.

Bringing it all together in the treatment of CINV: application of current knowledge into routine clinical practice

D. Warr, 2018, Supportive Care in Cancer.

WWPA: Factor Analysis of Young Driver Perceptions, Behaviours and Driving Experience. WWPB: Predictors of Time to First Crash for Young Drivers: Survival Analysis

D. Warr, 2009 .

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

E. Bruera, A. Molassiotis, M. Aapro, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital

G. Rodin, C. Zimmermann, D. Warr, 2006, Supportive Care in Cancer.

2016MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

E. Bruera, A. Molassiotis, M. Aapro, 2016 .

2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy

M. Aapro, F. Roila, A. Chan, 2016, Supportive Care in Cancer.

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.

M. Aapro, H. Schmoll, Li Zhang, 2015, The oncologist.

Management of highly emetogenic chemotherapy

D. Warr, 2012, Current opinion in oncology.

Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–55.

H. Muss, J. Herrstedt, D. Warr, 2006 .

Efficacy and tolerability of aprepitant for the prevention of chemotherapy‐induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy

H. Muss, A. Rodgers, F. Skobieranda, 2005, Cancer.

A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer

I. Tannock, G. Pond, M. Clemons, 2012, Breast Cancer Research and Treatment.

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

F. Shepherd, D. Walde, L. Yelle, 1995, Supportive Care in Cancer.

Quality of life studies in chemotherapy-induced emesis.

D. Osoba, B. Zee, J. Pater, 1996, Oncology.

Delayed emesis: moderately emetogenic chemotherapy

M. Tonato, L. Einhorn, F. Roila, 2005, Supportive Care in Cancer.

Evidence-based recommendations for the use of antiemetics in radiotherapy.

A. Molassiotis, F. Roila, I. Olver, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer

C. Erlichman, D. Warr, T. Gadalla, 2004, Breast Cancer Research and Treatment.

Acute emesis: moderately emetogenic chemotherapy

J. Koeller, F. Roila, J. Herrstedt, 2005, Supportive Care in Cancer.

Granisetron Pharmacoeconomic Evaluation of its Use in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting

A. Hisashige, V. Gebbia, D. Warr, 1996 .

Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.

C. Erlichman, D. Warr, S. Fine, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings—a meta-analysis

Linda Z Sun, A. Hinke, P. Hesketh, 2016, Supportive Care in Cancer.

Adult paratesticular sarcomas: a review of 21 cases.

C. Catton, B. O'Sullivan, B. Cummings, 1991, The Journal of urology.

What patients with cancer want to know about pain: a qualitative study.

Alejandro R Jadad, Jacqueline L Bender, Lorraine E Ferris, 2008, Journal of pain and symptom management.

The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options

Philippe Bédard, A. Razak, J. Lewin, 2017, Supportive Care in Cancer.

Small-cell carcinoma of the lung: derivation of a prognostic staging system.

U Sagman, J P Sculier, J. Sculier, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy- and cancer-related nausea and vomiting

D. Warr, 2008, Current oncology.

The Oral NK1 Antagonist Aprepitant for Prevention of Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy

K. Horgan, R. Wit, P. Hesketh, 2005 .

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

F. Roila, R. Gralla, R. de Wit, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer

D. Osoba, J. Pater, B. Zee, 1994, Quality of Life Research.

Supportive care in cancer—a MASCC perspective

F. Roila, C. Ripamonti, I. Olver, 2020, Supportive Care in Cancer.

Outcome and prognostic factors in soft tissue sarcoma in the adult.

C. Catton, B. O'Sullivan, R. Bell, 1993, International journal of radiation oncology, biology, physics.

A phase III randomized, double-blind, placebo-controlled study evaluating dextromethorphan plus slow-release morphine for chronic cancer pain relief in terminally ill patients.

E. Bruera, D. Tu, Sharon M. Watanabe, 2007, Journal of pain and symptom management.

Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

E. Warner, L. Yelle, J. Latreille, 1993, The New England journal of medicine.

Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.

E. Warner, I. Andrulis, P. Goss, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer

J. Hirsh, M. Gent, V. Bramwell, 1994, The Lancet.

A randomized, double-blinded study comparing six doses of batanopride (BMY-25801) with methylprednisolone in patients receiving moderately emetogenic chemotherapy.

D. Osoba, J. Pater, J. Latreille, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials

F. Roila, R. Gralla, K. Horgan, 2005 .

The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.

F. Roila, R. Gralla, K. Horgan, 2005, European journal of cancer.

Antiemetics in children receiving chemotherapy

F. Roila, I. Olver, R. Clark-Snow, 2005, Supportive Care in Cancer.

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

R. Gralla, H. Muss, A. Rodgers, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of postchemotherapy nausea and vomiting on health-related quality of life

D. Osoba, J. Pater, B. Zee, 1997, Supportive Care in Cancer.

Prognostic factors for chemotherapy induced nausea and vomiting.

D. Warr, 2014, European journal of pharmacology.

Antiemetic Therapy: Much Progress, Much More to be Done

Frcpc, D. Warr, 2007 .

The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy

D. Warr, 2006, Expert opinion on pharmacotherapy.

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

D. Johnston, D. Osoba, F. Shepherd, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antiemetics in children receiving chemotherapy

A. Molassiotis, F. Roila, I. Olver, 2005, Supportive Care in Cancer.

Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

M. Tonato, M. Aapro, L. Einhorn, 2011, Supportive Care in Cancer.

Acute emesis: moderately emetogenic chemotherapy

F. Roila, E. Bria, J. Herrstedt, 2010, Supportive Care in Cancer.

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

D. Tu, V. Bramwell, B. Norris, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.

V. Bramwell, K. Pritchard, H. Abu-Zahra, 1992, European journal of cancer.

Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada

Geoffrey Liu, J. Knox, R. Grant, 2020, Supportive Care in Cancer.

Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy

E. Perez, D. Gandara, M. Edelman, 1998, Supportive Care in Cancer.

Consensus Proposal for 5-HT3 Antagonists in the Prevention of Acute Emesis Related to Highly Emetogenic Chemotherapy

E. Perez, D. Gandara, M. Edelman, 1998 .

Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.

D. Osoba, A. Willan, C. Erlichman, 1991, Journal of the National Cancer Institute.

Do Correlates of Pain-Related Stoicism and Cautiousness Differ in Younger and Older People With Advanced Cancer?

F. Shepherd, M. Moore, G. Rodin, 2017, The journal of pain : official journal of the American Pain Society.

G. Rodin, C. Zimmermann, D. Warr, 2009, Pain medicine.

Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, M. Knowling, V. Bramwell, 1989, Journal of the National Cancer Institute.

Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.

R. Gralla, H. Muss, A. Rodgers, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting

D. Osoba, J. Pater, B. Zee, 1994, Supportive Care in Cancer.

A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.

D. Osoba, J. Pater, J. Latreille, 1992, European journal of cancer.

Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis

R. Chow, R. Navari, H. Lam, 2018, Supportive Care in Cancer.

Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.

D. Osoba, B. Zee, J. Pater, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.

D. Osoba, M. Fitch, D. Warr, 1995, The Canadian journal of oncology.

687 The oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: pooled data from 2 randomized, double-blind, placebo controlled trials

F. Roila, R. Gralla, K. Horgan, 2003 .

A Phase 2 study of perifosine in advanced or metastatic breast cancer

G. Pond, J. Dancey, D. Hedley, 2008, Breast Cancer Research and Treatment.

Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study

G. Pond, A. Robidoux, S. Chia, 2014, Breast Cancer Research and Treatment.

R. Dworkin, F. Shepherd, A. Macpherson, 2018, Pain medicine.

Cannabinoids as antiemetics: Everything that's old is new again.

D. Warr, P. Hesketh, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Psychometric Evaluation of the Pain Attitudes Questionnaire-Revised for People With Advanced Cancer.

F. Shepherd, M. Moore, G. Rodin, 2017, The journal of pain : official journal of the American Pain Society.

Acetaminophen (paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial.

M. Stockler, A. Pillai, J. Vardy, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the short-form McGill pain questionnaire-2 in younger and older people with cancer pain.

R. Melzack, R. Dworkin, F. Shepherd, 2014, The journal of pain : official journal of the American Pain Society.

Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.

C. Loprinzi, P. Goodwin, K. Pritchard, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art

R. Gralla, B. Espersen, S. Grunberg, 2011, Supportive Care in Cancer.

2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents

R. Gralla, A. Chan, P. Hesketh, 2016, Supportive Care in Cancer.

2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

M. Aapro, F. Roila, R. Gralla, 2016, Supportive Care in Cancer.

Can Patient Risk Factors Outperform Antiemetic Guidelines?: Choosing Wisely.

D. Warr, E. Chow, C. DeAngelis, 2016, JAMA Oncology.

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy

D. Warr, A. Carides, J. Street, 2011, Supportive Care in Cancer.

Identifying cancer patients at high risk for chemotherapy-induced nausea and vomiting (CINV): the development of a prediction tool

M. Aapro, G. Dranitsaris, M. Clemons, 2016 .

The Use of Gabapentin and Tricyclic Antidepressants in the Treatment of Neuropathic Pain in Cancer Patients

A. Jadad, M. Brouwers, D. Warr, 2013 .

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group.

N. Boyd, J. Ragaz, M. Knowling, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.

D. Payne, G. Deboer, R. Feld, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer

G. Lockwood, D. Warr, A. Cunningham, 1998, Psycho-oncology.

Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study

D. Cescon, Philippe Bédard, P. Goodwin, 2020, npj Breast Cancer.

The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine.

P. Band, N. Iscoe, J. Rusthoven, 1992, Journal of pain and symptom management.

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting—CME information

M. Aapro, M. Clemons, L. Schwartzberg, 2018, Supportive Care in Cancer.

A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.

C. Loprinzi, P. Goodwin, K. Pritchard, 2010 .

Coping, Catastrophizing and Chronic Pain in Breast Cancer

Scott R. Bishop, D. Warr, 2003, Journal of Behavioral Medicine.

The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer

V. Bramwell, K. Pritchard, M. Levine, 2012, Drugs.

Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials

Liying Zhang, H. Lam, D. Warr, 2014, Supportive Care in Cancer.

The communal coping model and cancer pain: the roles of catastrophizing and attachment style.

F. Shepherd, M. Moore, G. Rodin, 2012, Journal of Pain.

Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.

I. Tannock, D. Warr, S. Mckinney, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of palliative thoracic radiotherapy in non-small cell lung cancer.

A. Bezjak, M. Brundage, D. Warr, 1996, The Canadian journal of oncology.

Acceptance of pain: A study in patients with advanced cancer

G. Rodin, M. Moore, C. Zimmermann, 2009, Pain.

A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer

G. Lockwood, D. Warr, A. Cunningham, 1998, Psycho-oncology.

Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

A. Favero, D. Osoba, M. Kris, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer

Celeste Yu, Lisa Wang, Suzanne Kamel-Reid, 2017, Breast Cancer Research and Treatment.

Influence of measurement error on response rates.

I. Tannock, D. Warr, S. Mckinney, 1985, Cancer treatment reports.

Unconventional therapies for cancer: a refuge from the rules of evidence?

I. Tannock, D. Warr, 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

M. Kris, F. Roila, R. Gralla, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.